Nilsine Partners LLC purchased a new position in Encompass Health Corporation (NYSE:EHC - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 27,426 shares of the company's stock, valued at approximately $2,778,000.
Other institutional investors have also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. increased its stake in Encompass Health by 0.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 644,764 shares of the company's stock worth $59,544,000 after purchasing an additional 4,345 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S purchased a new position in Encompass Health during the 4th quarter valued at about $4,160,000. Fifth Third Bancorp grew its stake in Encompass Health by 88.7% during the 1st quarter. Fifth Third Bancorp now owns 4,290 shares of the company's stock valued at $434,000 after acquiring an additional 2,017 shares in the last quarter. US Bancorp DE grew its stake in Encompass Health by 9.6% during the 4th quarter. US Bancorp DE now owns 1,380 shares of the company's stock valued at $127,000 after acquiring an additional 121 shares in the last quarter. Finally, Farallon Capital Management LLC grew its stake in Encompass Health by 15,266.7% during the 4th quarter. Farallon Capital Management LLC now owns 461,000 shares of the company's stock valued at $42,573,000 after acquiring an additional 458,000 shares in the last quarter. Hedge funds and other institutional investors own 97.25% of the company's stock.
Insider Buying and Selling
In other news, EVP John Patrick Darby sold 10,000 shares of the company's stock in a transaction that occurred on Tuesday, April 29th. The stock was sold at an average price of $114.79, for a total transaction of $1,147,900.00. Following the completion of the transaction, the executive vice president now directly owns 79,710 shares in the company, valued at $9,149,910.90. The trade was a 11.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Mark J. Tarr sold 118,384 shares of the company's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $121.53, for a total value of $14,387,207.52. Following the transaction, the chief executive officer now owns 527,070 shares of the company's stock, valued at approximately $64,054,817.10. This trade represents a 18.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 132,663 shares of company stock worth $16,034,082. 2.00% of the stock is currently owned by insiders.
Analysts Set New Price Targets
Several equities analysts have weighed in on EHC shares. Wall Street Zen cut Encompass Health from a "strong-buy" rating to a "buy" rating in a research note on Friday, June 6th. Royal Bank Of Canada lifted their target price on Encompass Health from $110.00 to $125.00 and gave the company an "outperform" rating in a research note on Monday, April 28th. Truist Financial reaffirmed a "buy" rating and set a $135.00 target price (up previously from $116.00) on shares of Encompass Health in a research note on Monday, April 28th. Barclays lifted their target price on Encompass Health from $118.00 to $129.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. Finally, UBS Group boosted their price target on Encompass Health from $117.00 to $130.00 and gave the company a "buy" rating in a research note on Monday, April 28th. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Encompass Health has a consensus rating of "Buy" and a consensus target price of $127.00.
View Our Latest Analysis on EHC
Encompass Health Trading Down 0.6%
Shares of NYSE EHC opened at $119.07 on Friday. The business has a 50 day simple moving average of $115.81 and a 200 day simple moving average of $103.98. Encompass Health Corporation has a 52 week low of $82.74 and a 52 week high of $123.13. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.06 and a current ratio of 1.06. The stock has a market cap of $12.00 billion, a price-to-earnings ratio of 24.60, a PEG ratio of 2.43 and a beta of 0.89.
Encompass Health (NYSE:EHC - Get Free Report) last posted its earnings results on Thursday, April 24th. The company reported $1.37 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.18. Encompass Health had a return on equity of 17.63% and a net margin of 8.97%. The firm had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. During the same period in the previous year, the company earned $1.12 EPS. The company's revenue for the quarter was up 10.6% on a year-over-year basis. On average, research analysts predict that Encompass Health Corporation will post 4.8 earnings per share for the current fiscal year.
Encompass Health Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Tuesday, July 1st will be issued a $0.17 dividend. The ex-dividend date is Tuesday, July 1st. This represents a $0.68 annualized dividend and a yield of 0.57%. Encompass Health's dividend payout ratio (DPR) is currently 14.05%.
About Encompass Health
(
Free Report)
Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Encompass Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Encompass Health wasn't on the list.
While Encompass Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
